Key result
Dapagliflozin linked to a ~1.8-mL/m2 reduction in left atrial volume index in type 2 diabetes.
Observational (n=56)
No
Answers are grounded in this paper and cite their sources.
May indicate early LA remodeling benefit with dapagliflozin in T2D; leaves open effects on clinical outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2026) conducted an observational in Type 2 Diabetes without Heart Failure (n=56). Dapagliflozin vs. Baseline (pre-exposure) was evaluated on Left Atrial Volume Index (LAVI) in mL/m2 (MD -1.79, p=<0.001). In asymptomatic patients with type 2 diabetes, starting dapagliflozin significantly reduced Left Atrial Volume Index by 1.79 mL/m2 over 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: